08 December 2022, Columbia: To meet the rising demand of biological crop protection, Certis Biologicals today announced that it is strengthening its innovation pipeline by naming Mike Allan Vice President of Business Development and Licensing. As such, Allan will seek opportunities for the biologicals leader to expand innovation efforts through partnerships, licensing and potential acquisitions.
“There is staggering investment in the agriculture space right now and biologicals are at the forefront of many of those innovation efforts,” says Amy O’Shea, President and CEO. “With our strong commitment to science, the internal innovation possible at our laboratory facilities and our access to the market, we believe that we are a strong partner for emerging technology players. Mike’s industry breadth and respect will be key in leveraging these strengths for the overall growth of the sector.”
“Certis Biologicals has always been committed to bringing new technologies to the marketplace so that growers can feel comfortable protecting their crops and the environments in which they grow,” Allan says. “We have successfully launched many of these new advancements by leveraging partnerships with external collaborators such as W. Neudorff GmbH KG, Kaken Pharmaceutical Co., LTD and Novozymes. Dedication to this effort will bring vast opportunity to our innovation pipeline and to growers around the world who need additional crop protection tools.”
Allan joined Certis Biologicals in 2018 as Vice President, North America and has overseen sales operations, leading a team of sales professionals across North America through a period of significant growth and interest in biologicals. Prior to joining Certis, Allan served as President, North America of Isagro USA and in various roles at Arysta/Tomen, including Global Business Development Manager.
